Suspended

IPERPEEPIndividualized Positive End-expiRatory Pressure Guided by End-Expiratory Lung Volume in Moderate-to-severe Acute resPiratory Distress Syndrome.The IPERPEEP Study

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Invasive Mechanical ventilation

+ Neuromuscular Blocking Agents

+ Prone positioning

DeviceDrugProcedure
Who is being recruted

Lung Diseases+3

+ Respiration Disorders

+ Respiratory Distress Syndrome

From 18 to 85 Years
+20 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 3
Interventional
Study Start: November 2022
See protocol details

Summary

Principal SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: November 1, 2022

Actual date on which the first participant was enrolled.

ARDS patients with a PaO2/FiO2 ratio equal or below 150 mmHg (during mechanical ventilation with PEEP 5 cmH2O) will be enrolled within 24 hours from endo-tracheal intubation. To standardize lung volumes at study initiation, all patients will undergo mechanical ventilation with tidal volume set at 6 ml/kg of predicted body weight and PEEP set to obtain a plateau pressure within 28 and 30 cmH2O for thirty minutes (Express PEEP). Afterwards, a 5-step decremental PEEP trial will be conducted (Express PEEP to PEEP 5 cmH2O), and EELV will be measured at each step. PEEP-induced alveolar recruitment will be calculated for each PEEP range as the difference between PEEP-induced change EELV and the predicted increase in lung volume due to PEEP (PEEP-induced overdistension, equal to the product of respiratory system compliance and PEEP change). Patients will be then randomized to receive mechanical ventilation with PEEP set according to the optimal recruitment observed in the PEEP trial (IPERPEEP arm) trial or according to the Express strategy (Control arm, PEEP set to achieve a plateau pressure of 28-30 cmH2O). In both groups, tidal volume size, the use of prone positioning and neuromuscular blocking agents will be standardized. Primary endpoint of the study is a composite clinical outcome incorporating in-ICU mortality, 60-day ventilator free days and the area under the curve of serum Interleukin 6 over the course of the initial 72 hours. Primary and secondary endpoints will also be analyzed in subgroups, as defined below: * ∆EELV5-16/FRC ≥ 73% \[18\] during the PEEP trial * ∆EELV5-16/FRC < 73%\[23\] during the PEEP trial * Recruitment-to-inflation ratio (RI) ≥ 1 and <1 across the range between the lowest and highest PEEP tested during the PEEP trial * P/F ratio<100 mmHg at study inclusion * IL-6>400 pg/ml at study inclusion

Official TitleIndividualized Positive End-expiRatory Pressure Guided by End-Expiratory Lung Volume in Moderate-to-severe Acute resPiratory Distress Syndrome.The IPERPEEP Study
NCT04012073
Principal SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

18 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 85 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Lung DiseasesRespiration DisordersRespiratory Distress SyndromeRespiratory Tract DiseasesLung InjuryVentilator-Induced Lung Injury

Criteria

20 exclusion criteria prevent from participating
Pneumothorax;

Acute brain injury;

Pregnancy;

Clinical signs of history of decompensated heart failure (New York Heart Association class 3-4 before the acute phase of the disease or documented ejection fraction<35% or pulmonary capillary wedge pressure>18 mmHg) or acute coronary syndrome;

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Active Comparator
PEEP set so that the plateau pressure is within the following limits: 28 cmH2O≤Pplat≤ 30 cmH2O

Group II

Experimental
End expiratory lung volume (EELV) will be measured at each step during a 5-step decremental PEEP trial. PEEP will be ≥5 cmH2O and set to ensure the maximum recruitment observed in the PEEP trial, with a maximum permitted PPLAT of 30 cmH2O. In particular, when interpreting the results of the PEEP trial, recruitment-to-inflation (RI) ratio calculated across two adjacent PEEP levels will drive PEEP setting. * RI≥1.5 between two PEEP levels will lead to the setting of the higher PEEP. * RI\<0.5 will lead to the setting of the lower PEEP value. * In case of RI≥0.5 and \<1.5, the choice among two adjacent PEEP levels will be left to the attending physician, who will indicate the set PEEP in order to best balance between the commitment of limiting total, static and dynamic strain and of optimizing oxygenation and haemodynamics.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 10 locations

Suspended

Policlinico di Bari

Bari, ItalyOpen Policlinico di Bari in Google Maps
Suspended

Policlinico Sant'Orsola

Bologna, Italy
Suspended

Azienda ospedaliero-universitaria Mater Domini

Catanzaro, Italy
Suspended

SS. Annunziata hospital

Chieti, Italy
Suspended10 Study Centers